MYGN

Myriad Genetics, Inc. (NASDAQ:MYGN) is a genetic testing and precision medicine company founded in 1991 and headquartered in Salt Lake City, Utah. The company went public in 1995 and has evolved from a research-focused genomics company into a commercial leader in molecular diagnostics. Myriad develops and commercializes genetic tests primarily in oncology, women's health, and mental health applications, serving healthcare providers and patients in the United States and internationally. The company has built its reputation on pioneering work in hereditary cancer testing, particularly BRCA gene analysis, and has expanded its portfolio through both internal development and strategic acquisitions.